Much to the delight of Hemispherx BioPharma individual and institutional investors, a reader and follower of StocksHaven Investments has evaluated the Price Per Share potential should Ampligen see FDA approval within the coming weeks.

The following article has been submitted by an investor under the name: Ace Spader

The much anticipated FDA decision on the Hemispherx Biopharma, Inc. drug Ampligen has held a large audience of traders glued to their computers while tirelessly posting rants and raves in various trading forums across the web. Some of the most popular topics have included wild conspiracy theories surrounding the dilutions by the company and the delays by the FDA. Others have postulated about all of the potential uses of Ampligen in the future with a particular emphasis on the pandemic flu. Of all the topics seen on these boards there is one that continues to resurface multiple times

In the latest developments of Hemispherx BioPharma, BioMedReports analyzes and dissects the latest article from TheStreet.com with an interview involving Dr. Carter. If you are an avid fan of Ampligen and have invested in Hemispherx, this read is definitely worth your time. Article published by M.E. Garza of BioMedReports.com

“What do we think CFS is?” Dr. William Reeves asked a worldwide audience watching his streaming video presentation from the meeting for the Chronic Fatigue Syndrome Advisory Committee (CFSAC) of the Department of Health and Human Services in Washington, DC. on Thursday. “It’s a complex illness, with alterations in complex homeostatic systems. It’s not the result of a single mutation or a single environmental factor. It comes from a combination of many factors: genetics, gender, stressors, immune stressors all interact.”

Reeves is chief of the U.S.

Due to the explosive demand for BioPharma companies pending Food and Drug Approval on new and innovative drugs, I will begin focusing on companies which are a few weeks away from their reviews. Taking notice of the recent 3000%, and 1000% over night gains respectively of TTNP and VNDA, the risk versus rewards leans well towards the positive end on these choices.

Moreover, for those who are not high on risk tolerance, investing up to the FDA approval date may still be a very smart investment as these companies are poised to rise leading up to the decision.

Risk: You lose up to 40% as seen from DSCO and VION.OB and NFLD if approval is declined.

Now let’s move onto my first choice:

Hemispherx BioPharma, Inc

(Public, AMEX:HEB)

About: Hemispherx Biopharma, Inc.